Tibia fracture
diseaseOn this page
Also known as bone fracture of tibiatibia bone fracture
Summary
Tibia fracture (MONDO:0005320) is a disease with 1 GWAS associations across 19 studies and 25 clinical trials. Top therapeutic interventions include ibuprofen. A subtype of bone fracture — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 25
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | tibia fracture |
| Mondo ID | MONDO:0005320 |
| EFO | EFO:0003944 |
| MeSH | D013978 |
| SNOMED CT | 31978002 |
| Anatomy (UBERON) | UBERON:0000979 |
| Is cancer (heuristic) | no |
Also known as: bone fracture of tibia · tibia bone fracture
Data availability: 1 GWAS association (19 studies).
Disease family
This is a subtype of bone fracture. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: injury › bone fracture › tibia fracture
Related subtypes (6): spinal fracture, humerus fracture, ulna fracture, radius fracture, hip fracture, jaw fracture
Genetics & variants
GWAS landscape
1 GWAS associations across 19 studies. Top hits map to 1 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs12101819 | 3e-08 | NR2F2-AS1 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90479191 | Verma A | 2024 | 5,327 | 442,383 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90436815 | Zhou W | 2018 | 2,162 | 387,765 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90044634 | Jiang L | 2021 | 2,055 | 454,293 | A generalized linear mixed model association tool for biobank-scale data. |
| GCST90651619 | Liu TY | 2025 | 1,549 | 210,203 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90479190 | Verma A | 2024 | 1,423 | 119,527 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480972 | Verma A | 2024 | 1,423 | 119,527 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90081019 | Backman JD | 2021 | 762 | 387,022 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90085005 | Backman JD | 2021 | 762 | 387,022 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90077980 | Backman JD | 2021 | 693 | 331,061 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90081966 | Backman JD | 2021 | 693 | 331,061 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs12101819 | 15 | 96152505 | T>A | 0.05 | intron_variant | NR2F2-AS1 | 3e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Dibotermin Alfa | Approved (phase 4) |
| Eptotermin Alfa | Approved (phase 4) |
| Ibuprofen | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Somatropin.
Clinical trials & evidence
Clinical trials
Clinical trials: 25.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 22 |
| PHASE4 | 1 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04768478 | PHASE4 | WITHDRAWN | CBD for Pain Reduction and Opioid Use After Ankle and Tibia Fracture ORIF |
| NCT05000281 | PHASE3 | UNKNOWN | Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures |
| NCT00254514 | PHASE2 | COMPLETED | Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia Fractures |
| NCT05151926 | Not specified | RECRUITING | Limb Injuries and Post Injury Rehabilitation Trials - Tibial Shaft Fracture |
| NCT05668182 | Not specified | RECRUITING | A Case Series: TRUMATCH Graft Cage for Segmental Long Bone Defects |
| NCT05859451 | Not specified | RECRUITING | Effect of Tobacco Heating System (THS) on Closed Lower Limb Fracture Healing |
| NCT06586190 | Not specified | NOT_YET_RECRUITING | Outpatient Floor Pedal Bike Utilization |
| NCT07153302 | Not specified | RECRUITING | Assessing Bone Fracture Healing Effect of Almonds |
| NCT07193524 | Not specified | RECRUITING | Assessment of the Feasibility of Using a Preoperative Surgical Fracture Analysis Tool |
| NCT00240396 | Not specified | WITHDRAWN | Bimodal Analgesia as Form of Pain Control Post Long Bone Fracture |
| NCT00793637 | Not specified | COMPLETED | Evaluation of Handling and Possible Complications Related to the Newly Developed Angular Stable Locking System (ASLS) |
| NCT00888550 | Not specified | COMPLETED | Splinting Versus Not Splinting of the Distal Lower Extremity After Intramedullary Nailing for Tibial Fractures |
| NCT01047826 | Not specified | UNKNOWN | M.I.P.O. vs Intramedullary Nailing in Tibia Fractures |
| NCT01134354 | Not specified | COMPLETED | The Role of Patient Expectations in Traumatic Orthopedic Outcomes-TEFTOM EURASIA |
| NCT01282294 | Not specified | COMPLETED | Clinical Follow-up to Evaluate the Clinical Usefulness of Gentamicin-coated Titanium Nails in Tibia Fractures |
| NCT01691599 | Not specified | COMPLETED | Infection Rates Following Internal Fixation of Open and Closed Tibia Fractures in India |
| NCT03314623 | Not specified | COMPLETED | Immediate Mobilization After Plate Osteosynthesis of Proximal Tibial Fractures - A Cohort Study |
| NCT03649360 | Not specified | COMPLETED | Knee Pain After Intramedullary Nailing in the Tibia |
| NCT03936972 | Not specified | COMPLETED | Ilizarov Frame or Uni Planar External Fixator in the Cost-conscious Era |
| NCT04674592 | Not specified | UNKNOWN | Biomarkers in the Diagnosis of Acute Compartment Syndrome |
| NCT04960722 | Not specified | COMPLETED | OIF/β-TCP in Patients With Open Tibial Fractures in Need of Bone Grafting |
| NCT05613257 | Not specified | COMPLETED | Distal Targeter vs Free-hand |
| NCT06280417 | Not specified | UNKNOWN | Unreamed Intramedullary Tibial Nailing in Treatment of Open IIIa Diaphyseal Tibial Fractures in Adults |
| NCT06436365 | Not specified | COMPLETED | Is the Expert Nail With Poller Screws Superior to the Distal Tibial Locked Plate in the Management of Short Oblique Distal Tibial Fractures? |
| NCT07518836 | Not specified | TERMINATED | Efficacy and Safety of SurgiFill™in Patients With Femur or Tibia Fracture |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| IBUPROFEN | 4 | 1 |
Related Atlas pages
- Drugs: Ibuprofen